NUVB reports 25% quarter-over-quarter growth in IBTROZI sales, becoming ROS1 TKI market leader in first-line therapy.
Nuvation Bio reported IBTROZI net revenue of $23.2 million for Q2 2026, a 25% increase quarter-over-quarter. The company added approximately 160 new patients, with 85% starting first-line therapy.
The growth solidifies Nuvation Bio’s position as the ROS1 TKI market leader in first-line treatment. Management also outlined plans to expand safusidenib studies, with progression-free survival readouts expected in 2029.
The company previously secured a $30 million milestone payment from Eisai, aligning with its broader clinical and commercial expansion strategy.